MYO
Myomo, Inc.1.0400
+0.0400+4%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
39.97MP/E (TTM)
-Basic EPS (TTM)
-0.28Dividend Yield
0%Recent Filings
8-K
Q4 revenue $11.4M, FY $40.9M
10-K
FY2025 results
Myomo's FY2025 revenue jumped 26% to $40.9M, fueled by direct billing growth to $30.4M (up 20%) and international sales doubling to $6.8M, though VA revenue dipped 31%. Q4 momentum shone through operational tweaks slashing cycle times for faster revenue velocity despite a 27% backlog drop to 199 units; U.S. O&P channel doubled to $2.9M. Gross margins slipped to 65.7% on warranty costs, while operating expenses surged 40% to $41.3M, driving a $15.6M net loss versus $6.2M last year. Cash at $18.4M backs 2026 pivot to O&P and referrals, but Medicare reimbursement shifts threaten momentum.
8-K
Execs swap salary for RSUs
Myomo's Compensation Committee approved a salary-for-RSU program on December 10, 2025. CEO Paul Gudonis cut his 2026 base salary by 10% ($40,000 foregone), swapped for RSUs worth 115% of that. CFO David Henry did the same ($30,000 foregone). Executives align with shareholders. Company can scrap it before January 12, 2026 grants.
8-K
Myomo secures $17.5M debt facility
Myomo closed a $17.5M term loan facility with Avenue Venture on November 4, 2025, drawing $12.5M immediately while securing all assets. Interest floats at prime +4.75% (11.75% floor), with 18-month interest-only payments extendable to 24 months, maturing June 1, 2029; covenants demand $2.5M minimum cash and revenue/cash burn targets. Lenders hold warrants and $4M conversion rights into stock. Debt bolsters liquidity amid Q3 revenue growth to $10.1M.
10-Q
Q3 FY2025 results
Myomo posted Q3 revenue of $10.1M, up 10% y/y from $9.2M yet down q/q (derived), with gross margin slipping to 63.8% from 75.4% on higher material and manufacturing overhead costs. Direct billing held steady at 73% of sales while clinical providers jumped 56% y/y to $2.8M; operating loss widened to $3.5M from $1.0M as selling expenses climbed 54% on headcount and ads. Cash burned $13.4M YTD on ops, ending at $12.6M with $4.0M debt versus $4.0M revolver capacity; Avenue term loan closed post-quarter for $12.5M funded. Medicare Part B drove 54% of revenue. Reimbursement audits pose claim delays.
CVRX
CVRx, Inc.
8.32+0.14
DHAI
DIH Holding US, Inc.
0.75+0.16
DYNT
Dynatronics Corp.
0.04+0.00
EKSO
Ekso Bionics Holdings, Inc.
4.70+0.05
ELMD
Electromed, Inc.
29.88+0.28
LFWD
Lifeward Ltd.
0.64+0.02
MASI
Masimo Corporation
134.52-2.88
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NPCE
Neuropace, Inc.
15.88-0.04
OSSFF
EMBLA MEDICAL
5.33+0.00